Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2272 participants.

Also called NCT01841242

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 2,272 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01841242
  • EudraCT 2012-000803-33
Other papers using this trial's data
  • Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study Journal of the American College of Cardiology, 2026-01-20 DOI, PubMed 41562534

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01841242. Randomized; no masking; primary purpose prevention. Start 2013-04-23 (actual); primary completion 2021-01-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation
Acronym
CHLOVIS
Condition
Heart Failure
Condition
Arrhythmia
Intervention (Drug)
alcoholic povidone iodine
Intervention (Drug)
alcoholic chlorhexidine
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne (class: other)
Collaborator
Ministry of Health, France (class: other government)
Collaborator
C. R. Bard (class: industry)

Record details

Record id
cardio:ct-nct01841242
Content hash
237ffff0aa5e77788654843f554cbc4e977dfc7ec083ac236d3c57a964079232